Romero, A.; Laurent, C.; Lebourg, L.; Lemée, V.; Hanoy, M.; Le Roy, F.; Grange, S.; Lemoine, M.; Guerrot, D.; Bertrand, D.
Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? Viruses 2024, 16, 381.
https://doi.org/10.3390/v16030381
AMA Style
Romero A, Laurent C, Lebourg L, Lemée V, Hanoy M, Le Roy F, Grange S, Lemoine M, Guerrot D, Bertrand D.
Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? Viruses. 2024; 16(3):381.
https://doi.org/10.3390/v16030381
Chicago/Turabian Style
Romero, Anais, Charlotte Laurent, Ludivine Lebourg, Veronique Lemée, Mélanie Hanoy, Frank Le Roy, Steven Grange, Mathilde Lemoine, Dominique Guerrot, and Dominique Bertrand.
2024. "Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?" Viruses 16, no. 3: 381.
https://doi.org/10.3390/v16030381
APA Style
Romero, A., Laurent, C., Lebourg, L., Lemée, V., Hanoy, M., Le Roy, F., Grange, S., Lemoine, M., Guerrot, D., & Bertrand, D.
(2024). Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? Viruses, 16(3), 381.
https://doi.org/10.3390/v16030381
